The Lunsumio-based combination significantly improved progression-free survival, supporting plans to seek full approval and ...

Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and ...

Roche announced that the phase III CELESTIMO study evaluating Lunsumio (mosunetuzumab) in combination with lenalidomide versus MabThera/Rituxan (rituximab) plus lenalidomide in people with relapsed or ...

Genentech unit on Thursday announced a late-stage trial success for a combination regimen containing its bispecific antibody, ...

Roche Holdings AG ( RHHBY ), a biopharmaceutical company, on Thursday announced that the Phase 3 CELESTIMO trial for Lunsumio plus lenalidomide had met its primary endpoint in a comparative study for ...

Genentech, affiliated to Swiss drug major Roche Holding AG ( RHHBY ,RO.SW,ROG.SW), on Thursday announced that its Lunsumio-based regimen significantly improved progression-free survival in Follicular ...

You've heard of the four stages of the menstrual cycle—menstrual, follicular, ovulation, luteal—but, truth be told, it's been years since you took a sex-ed class and you could use a refresher course.

Please provide your email address to receive an email when new articles are posted on . Women who received COVID-19 vaccination in the follicular phase had longer menstrual cycles vs. before ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the Phase III CELESTIMO study evaluating Lunsumio® (mosunetuzumab-axgb) in combination with lenalidomide ...

Throughout the follicular phase, a single "dominant follicle" develops faster than the rest. This follicle (a fluid-filled sac in your ovary) then releases more estrogen into the body in preparation ...